{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:11:00Z","timestamp":1776543060514,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00417-018-4016-7","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T03:35:45Z","timestamp":1527737745000},"page":"1441-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience"],"prefix":"10.1007","volume":"256","author":[{"given":"Julie","family":"Blanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Deschasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Dot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-931X","authenticated-orcid":false,"given":"Alain-Marie","family":"Bron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"4016_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/archopht.124.5.726","volume":"124","author":"S Cugati","year":"2006","unstructured":"Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726\u2013732. \n                    https:\/\/doi.org\/10.1001\/archopht.124.5.726","journal-title":"Arch Ophthalmol"},{"key":"4016_CR2","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","volume":"8","author":"M Rehak","year":"2010","unstructured":"Rehak M, Wiedemann P (2010) Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 8:1886\u20131894. \n                    https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03909.x","journal-title":"J Thromb Haemost"},{"key":"4016_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313\u2013319 e311. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"key":"4016_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jth.12982","volume":"13","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, Lackner K, Pfeiffer N, Mirshahi A (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg health study. J Thromb Haemost 13:1254\u20131263. \n                    https:\/\/doi.org\/10.1111\/jth.12982","journal-title":"J Thromb Haemost"},{"key":"4016_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/IAE.0b013e3182870c15","volume":"33","author":"A Jaulim","year":"2013","unstructured":"Jaulim A, Ahmed B, Khanam T, Chatziralli IP (2013) Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33:901\u2013910. \n                    https:\/\/doi.org\/10.1097\/IAE.0b013e3182870c15","journal-title":"Retina"},{"key":"4016_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000327391","volume":"226","author":"G Coscas","year":"2011","unstructured":"Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, Mones J, de Smet M, Soubrane G, Staurenghi G (2011) Management of retinal vein occlusion\u2014consensus document. Ophthalmologica 226:4\u201328. \n                    https:\/\/doi.org\/10.1159\/000327391","journal-title":"Ophthalmologica"},{"key":"4016_CR7","doi-asserted-by":"publisher","first-page":"870987","DOI":"10.1155\/2015\/870987","volume":"2015","author":"RA Adelman","year":"2015","unstructured":"Adelman RA, Parnes AJ, Bopp S, Saad Othman I, Ducournau D (2015) Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int 2015:870987. \n                    https:\/\/doi.org\/10.1155\/2015\/870987","journal-title":"Biomed Res Int"},{"key":"4016_CR8","doi-asserted-by":"crossref","unstructured":"(1997) Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486\u2013491","DOI":"10.1001\/archopht.1997.01100150488006"},{"key":"4016_CR9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.ophtha.2017.03.060","volume":"124","author":"JP Ehlers","year":"2017","unstructured":"Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD, Bakri SJ (2017) Therapies for macular edema associated with branch retinal vein occlusion: a report by the American Academy of Ophthalmology. Ophthalmology 124:1412\u20131423. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.060","journal-title":"Ophthalmology"},{"key":"4016_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Group OGS (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134\u20131146 e1133. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.032","journal-title":"Ophthalmology"},{"key":"4016_CR11","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GSG, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453\u20132460. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.014","journal-title":"Ophthalmology"},{"key":"4016_CR12","unstructured":"SF0 Intravitreal Injection. French Society of Ophthalmology \n                    http:\/\/www.sfo.asso.fr\/files\/files\/\/FICHE-INFO-PATIENT_\/Fiche_65_Injection_intravitreenne_18janv16(1).pdf\n                    \n                  : Accessed 19 Feb2018"},{"key":"4016_CR13","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00417-016-3394-y","volume":"254","author":"JF Korobelnik","year":"2016","unstructured":"Korobelnik JF, Kodjikian L, Delcourt C, Gualino V, Leaback R, Pinchinat S, Velard ME (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254:2307\u20132318. \n                    https:\/\/doi.org\/10.1007\/s00417-016-3394-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4016_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/eye.2015.36","volume":"29","author":"V Fortoul","year":"2015","unstructured":"Fortoul V, Denis P, Kodjikian L (2015) Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study. Eye (Lond) 29:769\u2013775. \n                    https:\/\/doi.org\/10.1038\/eye.2015.36","journal-title":"Eye (Lond)"},{"key":"4016_CR15","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1111\/aos.12020","volume":"91","author":"A Bezatis","year":"2013","unstructured":"Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up\u2014the SOLO study. Acta Ophthalmol 91:e340\u2013e347. \n                    https:\/\/doi.org\/10.1111\/aos.12020","journal-title":"Acta Ophthalmol"},{"key":"4016_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/eye.2012.226","volume":"27","author":"E Moisseiev","year":"2013","unstructured":"Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A (2013) Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) 27:65\u201371. \n                    https:\/\/doi.org\/10.1038\/eye.2012.226","journal-title":"Eye (Lond)"},{"key":"4016_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","volume":"169","author":"H Hoerauf","year":"2016","unstructured":"Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO, Group C-CS (2016) Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258\u2013267. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2016.04.020","journal-title":"Am J Ophthalmol"},{"key":"4016_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000452896","volume":"236","author":"S Pommier","year":"2016","unstructured":"Pommier S, Meyer F, Guigou S, Barthelemy T, Gobert F, Hajjar C, Merite PY, Parrat E, Rouhette H, Matonti F (2016) Long-term real-life efficacy and safety of repeated Ozurdex(R) injections and factors associated with macular edema resolution after retinal vein occlusion: the REMIDO 2 study. Ophthalmologica 236:186\u2013192. \n                    https:\/\/doi.org\/10.1159\/000452896","journal-title":"Ophthalmologica"},{"key":"4016_CR19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/IAE.0000000000000851","volume":"36","author":"RP Danis","year":"2016","unstructured":"Danis RP, Sadda S, Jiao J, Li XY, Whitcup SM (2016) Relationship between retinal thickness and visual acuity in eyes with retinal vein occlusion treated with dexamethasone implant. Retina 36:1170\u20131176. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000000851","journal-title":"Retina"},{"key":"4016_CR20","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/IAE.0b013e318212e24d","volume":"31","author":"H Noma","year":"2011","unstructured":"Noma H, Funatsu H, Mimura T, Harino S, Shimada K (2011) Functional-morphologic correlates in patients with branch retinal vein occlusion and macular edema. Retina 31:2102\u20132108. \n                    https:\/\/doi.org\/10.1097\/IAE.0b013e318212e24d","journal-title":"Retina"},{"key":"4016_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/IAE.0b013e318297f842","volume":"34","author":"A Capone Jr","year":"2014","unstructured":"Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34:342\u2013351. \n                    https:\/\/doi.org\/10.1097\/IAE.0b013e318297f842","journal-title":"Retina"},{"key":"4016_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/IAE.0000000000000750","volume":"36","author":"SJ Bakri","year":"2016","unstructured":"Bakri SJ, Omar AF, Iezzi R, Kapoor KG (2016) Evaluation of multiple dexamethasone Intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 36:552\u2013557. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000000750","journal-title":"Retina"},{"key":"4016_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000442258","volume":"55","author":"C Chiquet","year":"2016","unstructured":"Chiquet C, Bron AM, Straub M, Dupuy C, Isaico R, Aptel F, Creuzot-Garcher C (2016) Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Res 55:152\u2013158. \n                    https:\/\/doi.org\/10.1159\/000442258","journal-title":"Ophthalmic Res"},{"key":"4016_CR24","doi-asserted-by":"publisher","first-page":"5831682","DOI":"10.1155\/2017\/5831682","volume":"2017","author":"A Pielen","year":"2017","unstructured":"Pielen A, Buhler AD, Heinzelmann SU, Bohringer D, Ness T, Junker B (2017) Switch of intravitreal therapy for macular edema secondary to retinal vein occlusion from anti-VEGF to dexamethasone implant and vice versa. J Ophthalmol 2017:5831682. \n                    https:\/\/doi.org\/10.1155\/2017\/5831682","journal-title":"J Ophthalmol"},{"key":"4016_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000473864","volume":"238","author":"J Hanhart","year":"2017","unstructured":"Hanhart J, Rozenman Y (2017) Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions. Ophthalmologica 238:110\u2013118. \n                    https:\/\/doi.org\/10.1159\/000473864","journal-title":"Ophthalmologica"},{"key":"4016_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000381187","volume":"53","author":"F Bandello","year":"2015","unstructured":"Bandello F, Parravano M, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G (2015) Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmic Res 53:207\u2013216. \n                    https:\/\/doi.org\/10.1159\/000381187","journal-title":"Ophthalmic Res"},{"key":"4016_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/IAE.0000000000001114","volume":"37","author":"AL Vie","year":"2017","unstructured":"Vie AL, Kodjikian L, Malcles A, Agard E, Voirin N, El Chehab H, Nguyen AM, Dot C (2017) Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma. Retina 37:173\u2013178. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001114","journal-title":"Retina"},{"key":"4016_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","volume":"256","author":"X Li","year":"2018","unstructured":"Li X, Wang N, Liang X, Xu G, Li XY, Jiao J, Lou J, Hashad Y, China Ozurdex in RVOSG (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:59\u201369. \n                    https:\/\/doi.org\/10.1007\/s00417-017-3831-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4016_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jop.2006.0067","volume":"23","author":"ER James","year":"2007","unstructured":"James ER (2007) The etiology of steroid cataract. J Ocul Pharmacol Ther 23:403\u2013420. \n                    https:\/\/doi.org\/10.1089\/jop.2006.0067","journal-title":"J Ocul Pharmacol Ther"},{"key":"4016_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","volume":"11","author":"MC Carnahan","year":"2000","unstructured":"Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11:478\u2013483","journal-title":"Curr Opin Ophthalmol"},{"key":"4016_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0733-8635(18)30318-8","volume":"10","author":"L Renfro","year":"1992","unstructured":"Renfro L, Snow JS (1992) Ocular effects of topical and systemic steroids. Dermatol Clin 10:505\u2013512","journal-title":"Dermatol Clin"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-4016-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T06:10:50Z","timestamp":1562911850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-4016-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4016"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-4016-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (place name of institute\/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}